Released Nov 13, 2020, after the close
10-Q filed Nov 13, 2020, 44 days after period end · 0001390478-20-000037
Q3 2020 · 10-Q
Revenue$0.00$0.00 no prior Q3 2019 on fileno prior Q2 2020 on file
Net Income-$4.47M-$4.47M N/M vs Q3 2019N/M vs Q2 2020
EPS Diluted-$0.53-$0.53 N/M vs Q3 2019N/M vs Q2 2020
Operating Income-$4,492,000—
Operating Cash Flowderived-$3,629,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Revenue | $0.00 | — | — | — |
| Net Income | -$4.47M | -$4.20M | -$290.00K | -$4.46M |
| EPS Diluted | -$0.53 | -$2.68 | -$26.75 | -$2.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR